Neurobehavioural and repeated-dose toxicity studies on the extractive from the decoction of a mixture of Alstonia boonei and Picralima nitida in mice

Pharmaceutical and Microbiological Standardization of Siculine Syrup® Formulation, an Antisickling Herbal Medicine

“…SE powder aqueous dispersions at 1 -6 mg/mL concentrations also demonstrated concentration-dependent reversal antisickling activities of 3.60 -64.73 % (Figure 2). At different test concentrations: 1, 2, 3, 4, 5, and 6 mg/mL, the PHBA-equivalent reversal antisickling activity (RAA) values of the SE powder activities were: 0.3, 0.4, 0.6, 1.0, 1.0, and 1.0, respectively; derived similarly from Figure 2 data as the quotient RAA values of SE versus PHBA activities (Ajayi et al, 2020). Thus, the relatively high reversal antisickling activities (61-66%) of SE powder at 4.0, 5.0 and 6.0 mg/mL concentrations (Figure 2) were equivalent to those of PHBA (positive control agent), as well as statistically comparable and equivalent to that of Ciklavit® activity (67.85±7.50 %).…”

“…Siculine extractive (SE) powder aqueous dispersions, at 1 -6 mg/mL concentrations, demonstrated concentrationdependent inhibitory antisickling activities of 23.16 -83.66 % (Figure 1). At different test concentrations: 1, 2, 3, 4, 5, and 6 mg/mL, the vanillic acid (VA)-equivalent inhibitory antisickling activity (IAA) values of the SE powder activities were: 5.7, 4.3, 2.6, 1.5, 1.3, and 1.2, respectively; derived from Figure 1 data as the quotient (value) of SE activities versus VA activities (Ajayi et al, 2020). Thus, SE powder exhibited greater inhibitory antisickling activities than the positive control, vanillic acid, at all the test concentrations (Figure 1).…”